A new first-line treatment involving the PD-1 inhibitor nivolumab for advanced-stage classic Hodgkin lymphoma could soon make its way into clinics.
Long-term data on patients treated with a standard chemoimmunotherapy combination show relapse rates dropped over time and 70% of patients were still alive 15 years later, with an overall cure rate estimated at 42% of patients treated, according to a study led by scientists at SWOG, Fred Hutch Cancer Center, and the University of Rochester Medical Center.
